STOCK TITAN

ANEW MEDICAL, INC. Strengthens Intellectual Property Protection with U.S. Patent Issuance for Its Secreted RNA Splice Variant of the Human Klotho Gene Used for the Treatment of Neurodegenerative and Age-Related Diseases

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Very Positive)
Tags

ANEW MEDICAL, INC. (NASDAQ: WENA) has been granted U.S. Patent No. 12,036,268 for its secreted RNA splice variant of the human Klotho gene, known as 's-KL'. This patent strengthens ANEW's intellectual property protection for developing treatments for neurodegenerative and age-related diseases. The Klotho gene, often called the 'anti-aging' gene, controls various brain and neurologic functions.

ANEW has exclusive worldwide rights to develop and commercialize novel genetic approaches for treating conditions like Alzheimer's, ALS, and Parkinson's disease. The company's IP portfolio is licensed from Universitat Autònoma de Barcelona and Institució Catalana De Recerca Estudis Avançats. This U.S. patent complements existing patents in Europe, China, and other Asian markets, solidifying ANEW's global IP position.

ANEW MEDICAL, INC. (NASDAQ: WENA) ha ricevuto il Brevetto Statunitense n. 12,036,268 per la sua variante di splicing RNA secreta del gene umano Klotho, conosciuta come 's-KL'. Questo brevetto rafforza la protezione della proprietà intellettuale di ANEW per lo sviluppo di trattamenti per le malattie neurodegenerative e legate all'età. Il gene Klotho, spesso chiamato gene 'anti-invecchiamento', controlla varie funzioni cerebrali e neurologiche.

ANEW detiene diritti esclusivi a livello mondiale per sviluppare e commercializzare approcci genetici innovativi per trattare condizioni come l'Alzheimer, la SLA e il morbo di Parkinson. Il portafoglio di proprietà intellettuale dell'azienda è concesso in licenza dalla Universitat Autònoma de Barcelona e dall'Institució Catalana De Recerca Estudis Avançats. Questo brevetto statunitense integra i brevetti esistenti in Europa, Cina e altri mercati asiatici, consolidando la posizione globale di proprietà intellettuale di ANEW.

ANEW MEDICAL, INC. (NASDAQ: WENA) ha obtenido la Patente de EE. UU. No. 12,036,268 para su variante de empalme de RNA secreta del gen humano Klotho, conocida como 's-KL'. Esta patente refuerza la protección de la propiedad intelectual de ANEW para desarrollar tratamientos para enfermedades neurodegenerativas y relacionadas con la edad. El gen Klotho, a menudo denominado gen 'anti-envejecimiento', controla diversas funciones cerebrales y neurológicas.

ANEW tiene derechos exclusivos a nivel mundial para desarrollar y comercializar enfoques genéticos novedosos para tratar condiciones como la enfermedad de Alzheimer, la ELA y el Parkinson. El portafolio de propiedad intelectual de la empresa está licenciado por la Universitat Autònoma de Barcelona y la Institució Catalana De Recerca Estudis Avançats. Esta patente estadounidense complementa las patentes existentes en Europa, China y otros mercados asiáticos, consolidando la posición global de propiedad intelectual de ANEW.

ANEW MEDICAL, INC. (NASDAQ: WENA)는 인간 Klotho 유전자의 분비 RNA 스플라이스 변이체인 's-KL'에 대해 미국 특허 제 12,036,268호를 획득했습니다. 이 특허는 신경퇴행성 질환 및 노화 관련 질병 치료 개발을 위한 ANEW의 지적 재산권 보호를 강화합니다. Klotho 유전자는 종종 '노화 방지' 유전자라고 불리며, 다양한 뇌 및 신경 기능을 조절합니다.

ANEW는 알츠하이머병, ALS 및 파킨슨병과 같은 질환 치료를 위한 새로운 유전적 접근 방식을 개발 및 상용화할 수 있는 전 세계 독점권을 보유하고 있습니다. 회사의 지적 재산 포트폴리오는 바르셀로나 자치대학교 및 카탈루냐 고등 연구 기관으로부터 라이센스가 부여되었습니다. 이 미국 특허는 유럽, 중국 및 기타 아시아 시장에서의 기존 특허를 보완하여 ANEW의 글로벌 지적 재산 위치를 강화합니다.

ANEW MEDICAL, INC. (NASDAQ: WENA) a obtenu le brevet américain n° 12,036,268 pour sa variante d'épissage d'ARN sécrétée du gène humain Klotho, connue sous le nom de 's-KL'. Ce brevet renforce la protection de la propriété intellectuelle d'ANEW pour le développement de traitements contre les maladies neurodégénératives et liées à l'âge. Le gène Klotho, souvent appelé gène 'anti-âge', contrôle diverses fonctions cérébrales et neurologiques.

ANEW détient des droits exclusifs dans le monde entier pour développer et commercialiser des approches génétiques innovantes pour traiter des affections telles que la maladie d'Alzheimer, la SLA et la maladie de Parkinson. Le portefeuille de propriété intellectuelle de l'entreprise est licencié par l'Universitat Autònoma de Barcelona et l'Institució Catalana De Recerca Estudis Avançats. Ce brevet américain complète les brevets existants en Europe, en Chine et dans d'autres marchés asiatiques, consolidant ainsi la position mondiale de propriété intellectuelle d'ANEW.

ANEW MEDICAL, INC. (NASDAQ: WENA) hat das US-Patent Nr. 12,036,268 für seine sekretierte RNA-Spleißvariante des menschlichen Klotho-Gens, bekannt als 's-KL', erhalten. Dieses Patent stärkt den Schutz des geistigen Eigentums von ANEW zur Entwicklung von Behandlungen für neurodegenerative und altersbedingte Krankheiten. Das Klotho-Gen, das oft als 'Anti-Aging'-Gen bezeichnet wird, steuert verschiedene Gehirn- und neurologische Funktionen.

ANEW besitzt weltweit exklusive Rechte zur Entwicklung und Vermarktung neuartiger genetischer Ansätze zur Behandlung von Erkrankungen wie Alzheimer, ALS und Parkinson. Das IP-Portfolio des Unternehmens wird von der Universitat Autònoma de Barcelona und der Institució Catalana De Recerca Estudis Avançats lizenziert. Dieses US-Patent ergänzt bestehende Patente in Europa, China und anderen asiatischen Märkten und festigt die globale IP-Position von ANEW.

Positive
  • Granted U.S. Patent No. 12,036,268 for secreted RNA splice variant of human Klotho gene
  • Strengthened intellectual property protection for neurodegenerative and age-related disease treatments
  • Exclusive worldwide rights for novel genetic approaches in treating Alzheimer's, ALS, and Parkinson's disease
  • Expanded global IP position with patents in U.S., Europe, China, Hong Kong, and Japan
Negative
  • None.

Insights

The issuance of U.S. Patent No. 12,036,268 for ANEW MEDICAL's secreted RNA splice variant of the human Klotho gene is a significant milestone in their intellectual property strategy. This patent, covering the 's-KL' variant for treating cognitive and neurodegenerative diseases, complements their existing patents in Europe, China and other Asian markets. The broad geographical coverage provides ANEW with a strong competitive advantage and potential licensing opportunities.

The patent's scope, encompassing treatment for Alzheimer's, ALS, Parkinson's and age-related disorders, positions ANEW at the forefront of the lucrative neurodegenerative disease market. This IP protection is important for attracting partnerships and investments, potentially accelerating the company's R&D efforts and time-to-market for their innovative therapies.

ANEW's focus on the Klotho gene, often called the "anti-aging" gene, is particularly intriguing. The 's-KL' variant's potential in treating cognitive and neurodegenerative diseases represents a novel approach in this field. The ability to replace or augment s-KL production could have far-reaching implications, not just for specific diseases but also for supporting longevity.

However, it's important to note that while promising, gene therapy approaches often face significant challenges in clinical development and regulatory approval. The transition from patent to marketable treatment is a long and complex process. Investors should closely monitor ANEW's progress in preclinical and clinical trials to assess the real-world potential of this patented technology.

The issuance of this U.S. patent strengthens ANEW MEDICAL's market position and potential valuation. With a comprehensive global IP portfolio now including the U.S., Europe, China, Hong Kong and Japan, ANEW has positioned itself as a key player in the neurodegenerative disease treatment market, estimated to reach $54 billion by 2026.

This patent issuance could catalyze several financial opportunities:

  • Increased attractiveness to potential partners or acquirers
  • Enhanced ability to secure funding for clinical trials
  • Potential for licensing revenues

However, investors should remain cautious. Despite the strong IP position, ANEW still faces the substantial costs and risks associated with drug development in the biotech sector. The company's financial health, cash runway and progression of its pipeline will be important factors to watch in the coming years.

Issuance of the Klotho gene-therapy patent will be instrumental in protecting ANEW’s IP for development and commercialization in the U.S.

NEW YORK, Aug. 15, 2024 (GLOBE NEWSWIRE) -- ANEW MEDICAL, INC. (“ANEW” or “the Company”) (NASDAQ: WENA) a U.S. -based biotechnology company focused on developing cell and gene-based treatments for aging, and age-related diseases, today announced the grant and issuance of U.S. Patent No. 12,036,268 (“the 268 patent”) covering the secreted RNA splice variant of the human Klotho gene, referred to as “s-KL”, for the treatment of cognitive and neurodegenerative diseases.

The human Klotho gene, sometimes referred to as the “anti-aging” gene, also controls many normal brain and neurologic functions. The Klotho gene-therapy patent in the U.S. is instrumental new intellectual property (“IP”) protecting its development and commercialization in the U.S. ANEW previously announced that patents have already been granted and issued in Europe, China, and other Asian markets.

ANEW’s IP portfolio has been licensed on an exclusive worldwide basis from the Universitat Autònoma de Barcelona (UAB) and Institució Catalana De Recerca Estudis Avançats (ICREA) in Barcelona, Spain, and provides ANEW with rights to develop and commercialize novel genetic approaches for the treatment of neurodegenerative diseases, including Alzheimer’s, amyotrophic lateral sclerosis (ALS or “Lou Gehrig’s disease”), Parkinson’s disease, and other age-related disorders. Replacing or augmenting the production of the gene product, s-KL, may also be used to support longevity.

“This is a major win for ANEW and our shareholders,” commented Dr. Joseph Sinkule, the Founder, Chairman and CEO of ANEW. “It provides us with the protection we need to successfully move forward with the development of our innovative protein, cell and gene therapies using our patented sequence and use of s-KL secreted Klotho RNA splice variant sequence and delivery systems to treat these devastating neurodegenerative diseases. With the issuance of this important patent in the USA, ANEW has secured an enviable global IP position with patents already issued in Europe, China, Hong Kong, and Japan.”

About ANEW MEDICAL, INC.
ANEW MEDICAL, INC. (NASDAQ: WENA) is a biopharmaceutical company specializing in the development of patented, novel disease-modifying technologies targeting the brain and central nervous system (CNS) that are seen as key developments in treating neurodegenerative and age-related disorders. The Company obtained exclusive worldwide rights to platform technologies and knowhow to develop cutting edge protein, gene and cell therapies to treat age-related pathologies such as Alzheimer’s and Parkinson’s Disease, ALS, multiple sclerosis and rare neurodegenerative diseases. The company is managed by a team of individuals and advisors who are highly experienced in biopharmaceutical product development and commercialization.

For more information, contact:
Eric Boyd
Investor Relations
Email: IR@anewmeds.com

Forward-Looking Statements:
This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Without limiting the generality of the foregoing, the forward-looking statements in this press release include descriptions of the Company’s future commercial operations. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, such as the Company’s inability to implement its business plans, identify and realize additional opportunities, or meet or exceed its financial projections and changes in the regulatory or competitive environment in which the Company operates. You should carefully consider the foregoing factors and the other risks and uncertainties described in the documents filed or to be filed by the Company with the U.S. Securities and Exchange Commission (the “SEC”) from time to time, which could cause actual events and results to differ materially from those contained in the forward-looking statements. Copies of these documents are available on the SEC’s website, www.sec.gov. All information provided herein is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.


FAQ

What is the significance of ANEW MEDICAL's new U.S. patent for the Klotho gene?

ANEW MEDICAL's new U.S. Patent No. 12,036,268 for the secreted RNA splice variant of the Klotho gene (s-KL) strengthens their intellectual property protection for developing treatments for neurodegenerative and age-related diseases. This patent is important for protecting ANEW's development and commercialization efforts in the U.S. market.

What diseases does ANEW MEDICAL (WENA) aim to treat with their Klotho gene therapy?

ANEW MEDICAL (WENA) aims to develop treatments for neurodegenerative and age-related diseases, including Alzheimer's, amyotrophic lateral sclerosis (ALS), Parkinson's disease, and other age-related disorders using their patented Klotho gene therapy approach.

In which countries does ANEW MEDICAL (WENA) now hold patents for their Klotho gene therapy?

ANEW MEDICAL (WENA) now holds patents for their Klotho gene therapy in the United States, Europe, China, Hong Kong, and Japan, establishing a strong global intellectual property position.

How might ANEW MEDICAL's (WENA) Klotho gene therapy potentially support longevity?

ANEW MEDICAL's (WENA) Klotho gene therapy, which involves replacing or augmenting the production of the s-KL gene product, may potentially support longevity. The Klotho gene is often referred to as the 'anti-aging' gene and controls many normal brain and neurologic functions.

ANEW MEDICAL, INC.

NASDAQ:WENA

WENA Rankings

WENA Latest News

WENA Stock Data

15.44M
21.26M
21.74%
12.21%
1.22%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
NEW YORK